Recent progress in the research of small molecule hiv-1 rnase h inhibitors

Current Medicinal Chemistry

Volumn 21, Issue 17, 2014, Pages 1956-1967

  Cao, Lili ^a   Song, Weiguo ^a   De Clercq, Erik ^b   Zhan, Peng ^a   Liu, Xinyong ^a  

^a BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

AIDS; Drug design; HIV 1; RNase H inhibitors; RT; SAR

Indexed keywords

AMIDE; ANTHRAQUINONE DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CARBOXYLIC ACID DERIVATIVE; DIKETO ACID INHIBITOR; DOUBLE STRANDED DNA; HUMAN IMMUNODEFICIENCY VIRUS 1 RIBONUCLEASE H INHIBITOR; HYPERICUM EXTRACT; HYPERICUM HIRCINUM EXTRACT; MAGNESIUM DERIVATIVE; N HYDROXYIMIDE DERIVATIVE; NAPHTHYRIDINONE DERIVATIVE; NATURAL PRODUCT; NITROFURAN 2 CARBOXYLIC ACID CARBAMOYLMETHYL ESTER DERIVATIVE; ORGANOPHOSPHATE; PYRIMIDINOL CARBOXYLIC ACID DERIVATIVE; PYRIMIDINONE DERIVATIVE; RIBONUCLEASE H; RIBONUCLEASE INHIBITOR; RNA; SINGLE STRANDED DNA; THIENOPYRIMIDINONE DERIVATIVE; THIOPHENE 3 CARBOXAMIDE DERIVATIVE; TRANSFER RNA; TROPOLONE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; BINDING SITE; CHEMICAL STRUCTURE; CRYSTAL STRUCTURE; DNA RNA HYBRIDIZATION; DNA SYNTHESIS; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME STRUCTURE; HIGH THROUGHPUT SCREENING; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROLYSIS; HYPERICUM; HYPERICUM HIRCINUM; IC 50; NONHUMAN; NUCLEOPHILICITY; PHYSICAL CHEMISTRY; PROTEIN FUNCTION; REVERSE TRANSCRIPTION; REVIEW; RNA DEGRADATION; SIGNAL TRANSDUCTION; STOICHIOMETRY; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION; VIRUS GENOME; VIRUS REPLICATION; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG DESIGN; DRUG EFFECTS; ENZYMOLOGY; HIV INFECTIONS; HUMAN; METABOLISM; VIROLOGY;

ANTI-HIV AGENTS; DRUG DESIGN; HIV INFECTIONS; HIV-1; HUMANS; MODELS, MOLECULAR; RIBONUCLEASE H, HUMAN IMMUNODEFICIENCY VIRUS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84899821420     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867321666140120121158     Document Type: Review

References (55)

1. UNAIDS, global AIDS report, 2012. http://www.unaids.org/en/resources/ publications/2012/name,76121,en.asp (Accessed November 21, 2013)
2. Tramontano, E. HIV-1 RNase H: recent progress in an exciting, yet little explored, drug target. Mini-Rev. Med. Chem., 2006, 6, 727-737.
3. Kohlstaedt, L.A.; Wang, J.; Friedman, J.M.; Rice, P.A.; Steitz, T.A. Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science, 1992, 256, 1783-1790.
4. Yu, F.; Liu, X.; Zhan, P; De Clercq, E. Recent advances in the research of HIV-1 RNase H inhibitors. Mini-Rev. Med. Chem., 2008, 8, 1243-1251.
5. Pari, K.; Mueller, G.A.; DeRose, E.F; Kirby, T.W.; London, R.E. Solution structure of the RNase H domain of the HIV-1 reverse transcriptase in the presence of magnesium. Biochemistry, 2003, 42, 639-650.
6. Nowotny, M.; Gaidamakov, S.A,; Crouch, R.J.; Yang, W. Crystal structures of RNase H bound to an RNA/DNA hybrid: substrate specificity and metal-dependent catalysis. Cell, 2005, 121, 1005-1016.
7. Arts, E.J.; Le Grice, S.F. Interaction of retroviral reverse transcriptase with template-primer duplexes during replication. Prog. Nucleic Acid Res. Mol. Biol., 1998, 58, 339-393.
8. Rausch, J.W.; Le Grice, S.F. 'Binding, bending and bonding': polypurinetract-primed initiaon of plus-strand DNA synthesis in human immunodeficiency virus. Int. J. Biochem. Cell. Biol., 2004, 36, 1752-1766.
9. Tramontano, E.; Di Santo, R. HIV-1 RT-associated RNase H function inhibitors: recent advances in drug development. Curr. Med. Chem., 2010, 17, 2837-2853.
10. Champoux, J.J.; Schultz, S.J. Ribonuclease H: properties, substrate specificity and roles in retroviral reverse transcription. FEBS J., 2009, 276, 1506-1516.
11. Schultz, S.J.; Champoux, J.J. RNase H activity: structure, specificity, and function in reverse transcription. Virus Res., 2008, 134, 86-103.
12. Huang, H.; Chopra, R.; Verdine, G.L.; Harrison, S.C. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science, 1998, 282, 1669-1675.
13. Nowotny, M.; Gaidarnakov, S.A.; Ghirlando, R.; Cerritelli,S.M.; Crouch, R.J.; Yang, W. Structure of human RNase H1 complexed with an RNA/DNA hybrid: insight into HIV reverse transcription. Mol. Cell., 2007, 28, 264-276.
14. Klumpp, K.; Mirzadegan, T. Recent progress in the design of small molecule inhibitors of HIV RNase H. Curr. Pharm. Drug, 2006, 12, 1909-1922.
15. Loya, S.; Tal, R.; Kashman, Y.; Hizi, A. Illimaquinone, a selective inhibitor of the RNase H activity of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother., 1990, 34, 2009-2012.
16. Parkes, K.E.; Ermet, P.; Fassler, J.; Ives, J.; Martin, J.A.; Merrett, J.H.; Obrecht, D.; Williams, G.; Klumpp, K. Use of a pharmacophore model to discover a new class of influenza endonuclease inhibitors. J. Med. Chem., 2003, 46, 1153-1164.
17. Klumpp, K.; Hang, J.Q.; Rajendran, S.; Yang, Y.; Derosier, A.; Wong Kai, P.; Overton, H.; Parkes, K.E.; Cammack, N.; Martin, J.A. Two-metal ion mechanism of RNA cleavage by HIV RNase H and mechanism-based design of selective HIV RNase H inhibitors. Nucleic Acids Res., 2003, 31, 6852-6859.
18. Hang, J.Q.; Rajendran, S.; Yang, Y.; Li, Y.; Wong Kai In, P.; Overton, H.; Parkes, K.E.; Cammack, N.; Martin, J.A.; Klumpp, K. Activity of the isolated HIV RNase H domain and specific inhibition by N-hydroxyimides. Biochem. Biophys. Res. Comm., 2004, 317, 321-329.
19. Billamboz, M.; Bailly, F.; Barreca, M.L.; De Luca, L.; Mouscadet, J.F.; Calmels, C.; Andréola, M.L.; Witvrouw, M.; Christ, F.; Debyser, Z.; Cotelle, P. Design, synthesis, and biological evaluation of a series of 2-hydroxyiso-quinoline-1,3(2H, 4H)-diones as dual inhibitors of human immunodeficiency virus type 1 integrase and the reverse transcriptase RNase H domain. J. Med. Chem., 2008, 51, 7717-7730.
20. Billamboz, M.; Bailly, F.; Lion, C.; Touati, N.; Vezin, Herve.; Calmels, C.; Andreola, M.L.; Christ, F.; Debyser, Z.; Cotelle, P. Magnesium chelating 2-hydroxy-isoquinoline-1,3(2H,4H)-diones, as inhibitors of HIV-1 integrase and/or the HIV-1 reverse transcriptase ribonuclease H domain: discovery of a novel selective inhibitor of the ribonuclease H function. J. Med. Chem., 2011, 54, 1812-1824.
21. Budihas, S.R.; Gorshkova, I.; Gaidamakov, S.; Wamiru, A.; Bona, M.K.; Parniak, M.A.; Crouch, R.J.; McMahon, J.B.; Beutler, J.A.; Le Grice, S.F. Selective inhibition of HIV-1 reverse transcriptaseassociated ribonuclease H activity by hydroxylated tropolones. Nucleic Acids Res., 2005, 33, 1249-1256.
22. Himmel, D.M.; Maegley, K.A.; Pauly, T.A.; Bauman, J.D.; Das, K.; Dharia, C.; Clark, A.D. Jr.; Ryan, K.; Hickey, M.J.; Love, R.A.; Hughes, S.H.; Bergqvist, S.; Arnold, E. Structure of HIV-1 reverse transcriptase with the inhibitor -thujaplicinol bound at the RNase H active site. Structure, 2009, 17, 1625-1635.
23. Chung, S.; Himmel, D.M.; Jiang, J.; Wojtak, K.; Bauman, J.D.; Rausch, J.W.; Wilson, J.A.; Beutler, J.A.; Thomas, C.J.; Arnold, E.; Le Grice, S.F. Synthesis, activity, and structural analysis of novel -hydroxytropolone inhibitors of human immunodeficiency virus reverse transcriptase-associated ribonuclease H. J. Med. Chem., 2011, 54, 4462-4473.
24. Tarrago, L.L.Andreola, M.L.; Fournier, M.; Nevinsky, G.A.; Parissi, V.; de Soultrait, V.R.; Litvak, S. Inhibitors of HIV-1 reverse transcriptase and integrase: classical and emerging therapeutical approaches. Curr. Pharm. Des., 2002, 8, 595-614.
25. Shaw-Reid, C.A.; Munshi, V.; Graham, P.; Wolfe, A.; Witmer, M.; Danzeisen, R.; Olsen, D.B.; Carroll, S.S.; Embrey, M.; Wai, J.S.; Miller, M.D.; Cole, J.L.; Hazuda, D.J. Inhibition of HIV-1 ribonuclease H by a novel diketo acid, 4-[5-(benzoylamino)thien-2-yl]-2,4-dioxo-butanoic acid. J. Biol. Chem., 2003, 278, 2777-2780.
26. Tramontano, E.; Esposito, F.; Badas, R.; Di Santo, R.; Costi, R.; La Colla, P. 6-[1-(4-Fluorophenyl)methyl-1H-pyrrol-2-yl)]-2,4-dioxo-5-hexenoic acid ethyl ester a novel diketo acid derivative which selectively inhibits the HIV-1 viral replication in cell culture and the ribonuclease H activity in vitro. Antiviral. Res., 2005, 65, 117-124.
27. Kirschberg, T.A.; Balakrishnan, M.; Squires, N.H.; Barnes, T.; Brendza, K.M.; Chen, X.; Eisenberg, E.J.; Jin, W.; Kutty, N.; Leavitt, S.; Liclican, A.; Liu, Q.; Liu, X.; Mak, J.; Perry, J.K.; Wang, M.; Watkins, W.J.; Lansdon, E.B. RNase H active site inhibitors of human immunodeficiency virus type 1 reverse transcriptase: design, biochemical activity, and structural information. J. Med. Chem., 2009, 52, 5781-5784.
28. Lansdon, E.B.; Liu, Q.; Leavitt, S.A.; Balakrishnan, M.; Perry, J.K.; Lancaster-Moyer, C.; Kutty, N.; Liu, X.; Squires, N.H.; Watkins, W.J.; Kirschberg, T.A. Structural and binding analysis of pyrimidinol carboxylic acid and N-hydroxy-quinazolinedione HIV-1 RNase H inhibitors. Antimicrob. Agents Chemother., 2011, 55, 2905-2915.
29. Williams, P.D.; Staas, D.D.; Venkatraman, S.; Loughran, H.M.; Ruzek, R.D.; Booth, T.M.; Lyle, T.A.; Wai, J.S.; Vacca, J.P.; Feuston, B.P.; Ecto, L.T.; Flynn, J.A.; DiStefano, D.J.; Hazuda, D.J.; Bahnck, C.M.; Himmelberger, A.L.; Dornadula, G.; Hrin, R.C.; Stillmock, K.A.; Witmer, M.V.; Miller, M.D.; Grobler, J.A. Potent and selective HIV-1 Ribonuclease H inhibitors based on a 1-hydroxy-1,8-naphthyridin-2(1H)-one scaffold. Bioorg. Med. Chem. Lett., 2010, 20, 6754-6757.
30. Fuji, H.; Urano, E.; Futahashi, Y.; Hamatake, M.; Tatsumi, J.; Hoshino, T.; Morikawa, Y.; Yamamoto, N.; Komano, J. Derivatives of 5-nitro-furan-2- carboxylic acid carbamoylmethyl ester inhibit RNase H activity associated with HIV-1 reverse transcriptase. J. Med. Chem., 2009, 52, 1380-1387.
31. Yanagita, H.; Urano, E.; Matsumoto, K.; Ichikawa, R.; Takaesu, Y.; Ogata, M.; Murakami, T.; Wu, H.; Chib, J.; Komano, J.; Hoshino, T. Structural and biochemical study on the inhibitory activity of derivatives of 5-nitro-furan-2-carboxylic acid for RNase H function of HIV-1 reverse transcriptase. Bioorg. Med. Chem., 2011, 19, 816-825.
32. Himmel, D.M.; Sarafianos, S.G.; Dharmasena, S.; Hossain, M.M.; McCoy-Simandle, K.; Ilina, T.; Clark, A.D.Jr.; Knight, J.L.; Julias, J.G.; Clark, P.K.; Krogh-Jespersen, K.; Levy, R.M.; Hughes, S.H.; Parniak, M.A.; Arnold, E. HIV-1 reverse transcriptase structure with RNase H inhibitor dihydroxy benzoyl naphthyl hydrazone bound at a novel site. ACS Chem. Biol., 2006, 1, 702-712.
33. Gong, Q.; Menon, L.; Ilina, T.; Miller, L.G.; Ahn, J.; Parniak, M.A.; Ishima, R. Interaction of HIV-1 reverse transcriptase ribonuclease H with an acylhydrazone inhibitor. Chem. Biol. Drug Des., 2010, 77, 39-47.
34. Wendeler, M.; Lee, H.F.; Bermingham, A.; Miller, J.T.; Chertov, O.; Bona, M.K.; Baichoo, N.S.; Ehteshami, M.; Beutler, J.; O'Keefe, B.R.; Götte, M.; Kvaratskhelia, M.; Le Grice, S. Vinylogous ureas as a novel class of inhibitors of reverse transcriptaseassociated ribonuclease H activity. ACS Chem. Biol., 2008, 3, 635-644.
35. Chung, S.; Wendeler, M.; Rausch, J.W.; Beilhartz, G.; Gotte, M.; O'Keefe, B. R.; Bermingham, A.; Beutler, J.A.; Liu, S.; Zhuang, X.; Le Grice, S.F. Structure-activity analysis of vinylogous urea inhibitors of human immunodeficiency virus-encoded ribonuclease H. Antimicrob. Agents Chemother., 2010, 54, 3913-3921.
36. Masaoka T.; Chung S.; Caboni P.; Rausch J.W.; Wilson J.A.; Taskent-Sezgin H.; Beutler J.A.; Tocco G.; Le Grice S.F. Exploiting drug-resistant enzymes as tools to identify thienopyrimidinone inhibitors of human immunodeficiency virus reverse transcriptaseassociated ribonuclease H. J. Med. Chem., 2013, 56, 5436-5445.
37. Medina-Franco, J.L.; Giulianotti, M.A.; Welmaker, G.S.; Houghten, R.A. Shifting from the single to the multitarget paradigm in drug discovery. Drug Discov. Today, 2013, 18, 495-501.
38. Zhan, P.; Liu, X. Designed multiple ligands: an emerging anti-HIV drug discovery paradigm. Curr. Pharm. Des., 2009, 15, 1893-917.
39. Zhan, P.; Liu, X. Rationally designed multitarget anti-HIV agents. Curr. Med. Chem., 2013, 20, 1743-58.
40. Wang, Z.; Bennett, E.M.; Wilson, D.J.; Salomon, C.; Vince, R. Rationally designed dual inhibitors of HIV reverse transcriptase and integrase. J. Med. Chem., 2007, 50, 3416-3419.
41. Wang, Z.; Vince, R. Design and synthesis of dual inhibitors of HIV reverse transcriptase and integrase: introducing a diketoacid functionality into delavirdine. Bioorg. Med. Chem., 2008, 16, 3587-3595.
42. Andréol, M.L. Closely related antiretroviral agents as inhibitors of two HIV-1 enzymes, ribonuclease H and integrase: killing two birds with one stone. Curr. Pharm. Des., 2004, 10, 3713-3723.
43. Di Santo, R. Diketo acids derivatives as dual inhibitors of human immunodeficiency virus type 1 integrase and the reverse transcriptase RNase H domain. Curr. Med. Chem., 2011, 18, 3335-3342.
44. Costi R.; Métifiot M.; Esposito F.; Cuzzucoli Crucitti G.; Pescatori L.; Messore A.; Scipione L.; Tortorella S.; Zinzula L.; Marchand C.; Pommier Y.; Tramontano E.; Di Santo R. 6-(1-Benzyl-1Hpyrrol-2-yl)-2,4-dioxo-5- hexenoic acids as dual inhibitors of recombinant HIV-1 integrase and ribonuclease H, synthesized by a parallel synthesis approach. J. Med. Chem., 2013, doi: 10.1021/jm401040b.
45. de Soultrait, V.R.; Lozach, P.Y.; Altmeyer, R.; Tarrago-Litvak, L.; Litvak, S.; Andréola, M.L. DNA aptamers derived from HIV-1 RNase H inhibitors are strong anti-integrase agents. J. Mol. Biol., 2002, 324, 195-203.
46. Marchand, C.; Beutler, J. A.; Wamiru, A.; Budihas, S.; Möllmann, U.; Heinisch, L.; Mellors, J.W.; Le Grice, S.F.; Pommier, Y. Madurahydroxylactone derivatives as dual inhibitors of human immunodeficiency virus type 1 integrase and RNase H. Antimicrob. Agents Chemother., 2008, 52, 361-364.
47. Dat, N.T.; Bae, K.H.; Wamiru, A.; McMahon, J.B.; Le Grice, S.F.J.; Bona, M.; Beutler, J.A.; Kim, Y.H. A dimeric lactone from Ardisia japonica with inhibitory activity for HIV-1 and HIV-2 ribonuclease H. J. Nat. Prod., 2007, 70, 839-841.
48. Takada, K.; Bermingham, A.; O'Keefe, B.R.; Wamiru, A.; Beutler, J.A.; Le Grice, S.F.J.; Lloyd, J.; Gustafson, K.R.; McMahon, J.B. An HIV RNase H inhibitory 1, 3, 4, 5-tetragalloylapiitol from the african plant Hylodendron gabunensis. J. Nat. Prod., 2007, 70, 1647-1649.
49. Bokesch, H.R.; Wamiru, A.; Le Grice, S.F.J.; Beutler, J.A.; McKee, T.C.; McMahon, J.B. HIV-1 Ribonuclease H inhibitory phenolic glycosides from Eugenia hyemalis. J. Nat. Prod., 2008, 71, 1634-1636.
50. Kim, J.A.; Yanga, S.Y.; Wamiru, A.; McMahon, J.B.; Le Grice, S.F.; Beutler, J.A.; Kim. Y.H. New monoterpene glycosides and phenolic compounds from Distylium racemosum and their inhibitory activity against ribonuclease H. Bioorg. Med. Chem. Lett., 2011, 21, 2840-2844.
51. Esposito F.; Kharlamova T.; Distinto S.; Zinzula L.; Cheng Y.C.; Dutschman G.; Floris G.; Markt P.; Corona A.; Tramontano E. Alizarine derivatives as new dual inhibitors of the HIV-1 reverse transcriptase-associated DNA polymerase and RNase H activities effective also on the RNase H activity of non-nucleoside resistant reverse transcriptases. FEBS J., 2011, 278, 1444-1457.
52. Esposito F.; Corona A.; Zinzula L.; Kharlamova T.; Tramontano E. New anthraquinone derivatives as inhibitors of the HIV-1 reverse transcriptase-associated ribonuclease H function. Chemotherapy, 2012, 58, 299-307.
53. Esposito F.; Sanna C.; Del Vecchio C.; Cannas V.; Venditti A.; Corona A.; Bianco A.; Serrilli A.M.; Guarcini L.; Parolin C.; Ballero M.; Tramontano E. Hypericum hircinum L. components as new single-molecule inhibitors of both HIV-1 reverse transcriptaseassociated DNA polymerase and ribonuclease H activities. Pathog. Dis., 2013, 68, 116-124.
54. Poongavanam V.; Kongsted J. Virtual screening models for prediction of HIV-1 RT associated RNase H inhibition. PLoS One., 2013, doi: 10.1371/journal.pone.0073478.
55. Esposito F.; Tramontano E. Past and future. Current drugs targeting HIV-1 integrase and reverse transcriptase-associated ribonuclease H activity: single and dual active site inhibitors. Antivir. Chem. Chemother., 2013, doi: 10.3851/IMP2690.